金吾财讯 | 美股医疗保健板块持续走强，标普500医疗保健市值加权指数、等权重指数双双刷新历史新高，市值加权指数升至1962.95点，等权重基准来到22221.73点，本轮上涨不再仅由板块内大市值龙头驱动。经历 2022-2023年板块低迷后，医疗保健板块在2026年重新积聚上涨动能。榜单筛选市值超100亿美元的大盘标的，覆盖管理式医疗、生物技术、医疗服务、医疗技术多条细分赛道，企业商业模式与业务敞口各有差异。Centene Corporation（CNC）以4.97分接近满分的量化评分位居榜单首位；Corcept Therapeutics（CORT）、Bright Spring Health Services（BTSG）紧随其后，评分分别为4.93、4.91；Halozyme Therapeutics（HALO）、Humana（HUM）跻身前五，均获强烈“买入”评级。VeevaSystems（VEEV）、Solventum（SOLV）分别拿到4.62、4.55分，为“强烈买入”；Neurocrine Biosciences（NBIX）、Da Vita（DVA）获得买入评级；United Health Group（UNH）评级为“持有”，评分3.48。即便板块整体处在历史高位，个股之间量化评分分化依旧显著。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.